Rescue of ApoE4-related lysosomal autophagic failure in Alzheimer's disease by targeted small molecules
by Balasubramaniam, M.; Narasimhappagari, J.; Liu, L.; Ganne, A.; Ayyadevara, S.; Atluri, R.; Ayyadevara, H.; Caldwell, G.; Reis, R. J. S.; Barger, S. W.; Griffin, W. S. T.
Homozygosity for the epsilon 4 allele of APOE increases the odds of developing Alzheimer's by 12 to 15 times relative to the most common epsilon 3;epsilon 3 genotype, and its association with higher plaque loads comports with evidence that APOE epsilon 4 compromises autophagy. The ApoE4 protein specifically binds a cis element ("CLEAR") in the promoters of several autophagy genes to block their transcription. We used a multifaceted approach to identify a druggable site in ApoE4, and virtual screening of lead-like compounds identified small molecules that specifically bind to this site to impede ApoE4::DNA binding. We validated these molecules both in vitro and in vivo with models expressing ApoE4, including ApoE4 targeted-replacement mice. One compound was able to significantly restore transcription of several autophagy genes and protected against amyloid-like aggregation in a C. elegans AD model. Together, these findings provide proof-of-principle evidence for pharmacological remediation of lysosomal autophagy by ApoE4 via ApoE4-targeted lead molecules that represent a novel tack on neurodegenerative disorders.In-silico based in vitro and in vivo validations identified a lead molecule that specifically targets: ApoE4 protein; inhibits ApoE4::CLEAR DNA binding; rescues thwarted lysosomal autophagy; and protects against A beta aggregation.
- Journal
- Communications Biology
- Volume
- 7
- Issue
- 1
- Year
- 2024
- URL
- https://dx.doi.org/10.1038/s42003-024-05767-9
- ISBN/ISSN
- 2399-3642
- DOI
- 10.1038/s42003-024-05767-9